Related Experiment Video

Updated: Aug 11, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Constitutive receptor activity series: endogenous inverse agonists and constitutive receptor activity in the

Roger A H Adan1

  • 1Rudolf Magnus Institute of Neuroscience, Department of Pharmacology and Anatomy, University Medical Center Utrecht, PO Box 85060, 3508 AB, Utrecht, The Netherlands. r.a.h.adan@med.uu.nl

Trends in Pharmacological Sciences
|February 28, 2006
PubMed

Insights

Melanocortin receptor mutations in obese individuals highlight the importance of constitutive receptor activity. This activity, regulated by an endogenous inverse agonist, is crucial for controlling body weight and pigmentation.

Area of Science:

  • Endocrinology
  • Genetics
  • Physiology

Background:

  • Constitutive melanocortin receptor activity is physiologically relevant.
  • Endogenous inverse agonists regulate melanocortin receptor activity.
  • Melanocortin receptor signaling impacts body weight and pigmentation.

Purpose of the Study:

  • To investigate the role of constitutive melanocortin receptor activity in obesity.
  • To explore the function of endogenous inverse agonists in regulating receptor signaling.
  • To understand the link between melanocortin receptor signaling, body weight, and coat color.

Main Methods:

  • Analysis of melanocortin receptor mutations in obese individuals.
  • Studies using genetically modified mice lacking endogenous melanocortin receptor agonists.

Main Results:

  • Mutations decreasing constitutive melanocortin receptor activity are found in obese individuals.
  • Differences in coat color in mice correlate with varying levels of constitutive melanocortin receptor signaling.
  • Endogenous inverse agonists modulate constitutive receptor activity.

Conclusions:

  • Regulation of constitutive melanocortin receptor activity is vital for maintaining body-weight homeostasis.
  • Constitutive melanocortin receptor signaling, controlled by inverse agonists, influences pigmentation.
  • Targeting melanocortin receptor pathways may offer therapeutic strategies for obesity and related disorders.

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Spare Receptors01:30

Spare Receptors

Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...